GlassScriptPhysician profile
Carrie Happ-Smith
NPI 1124306485
$3,721.50
in general payments reported to CMS, 2019-2025
27 companies · $999 in 2025
The $999 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $320 · 2021: $275 · 2022: $273 · 2023: $587 · 2024: $803 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,387.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $937.82 | 2019-2025 | Argos, Unity, Rocklatan |
| Bausch & Lomb Americas INC. | $278.43 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Oyster Point Pharma, INC. | $276.95 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sight Sciences, INC. | $243.08 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $229.12 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $227.65 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $200.69 | 2019-2021 | |
| Allergan, INC. | $195.24 | 2019-2021 | |
| Abbvie INC. | $146.40 | 2022-2025 | |
| New World Medical,INC. | $135.09 | 2021-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Sun Pharmaceutical Industries INC. | $116.78 | 2019-2025 | |
| Harrow Eye, LLC | $105.71 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $77.00 | 2024-2025 | |
| Dompe US, INC. | $68.00 | 2024-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $53.91 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $52.05 | 2023 | Acthar |
| Thea Pharma INC. | $50.87 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $44.74 | 2023 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Shire North American Group INC | $42.58 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $40.37 | 2019-2022 | |
| Amgen INC. | $31.40 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $31.10 | 2019-2021 | |
| Omeros Corporation | $23.45 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Astellas Pharma US INC | $17.49 | 2023 | Izervay |
| Ocular Therapeutix, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Happ-Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.